Literature DB >> 16435377

Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer.

Gerardo Quezada1, Theresa Sunderland, Ka Wah Chan, Kenneth Rolston, Craig A Mullen.   

Abstract

BACKGROUND: A number of clinical trials have employed clinical criteria that can identify pediatric patients at low-risk for complicated episodes of fever and neutropenia (F&N) and have successfully treated low-risk patients in the outpatient setting. Despite this, inpatient management remains the standard of care. This trial tested the hypothesis that a strategy of initial hospitalization followed by continuation of therapy in the outpatient setting could be practically implemented in the majority of episodes. PROCEDURE: Patients presenting with F&N were initially evaluated to determine if they had high-risk clinical criteria that would exclude them from this approach. Eligible patients were then hospitalized and treated with iv antibiotics. On subsequent days the attending physician determined whether the patient had exhibited improvement and could continue therapy in the outpatient setting with oral antibiotics. Outpatients were seen three times weekly and continued antibiotics until recovery from F&N.
RESULTS: Outpatient oral antibiotic therapy was practically implemented in less than one-quarter of episodes of pediatric F&N. Forty-nine percent of episodes were excluded from study by medical and social protocol exclusion criteria. One hundred five episodes were enrolled and among these 59 episodes included outpatient management. Common barriers to outpatient care included serious medical comorbidities, non-medical barriers including language and distance of residence from the medical center, and lack of interest. The average duration of outpatient care was 3.6 days following an average of 3.5 days of hospitalization. Ninety percent did not require rehospitalization. They experienced no complications.
CONCLUSIONS: In only a minority of episodes can outpatient antibiotic management be implemented. Medical comorbidities and social barriers can make the transition to outpatient care difficult. However, initial hospitalization followed by oral antibiotic outpatient management appears safe and effective for low-risk patients who exhibit good responses to initial antibiotic therapy in hospital. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16435377     DOI: 10.1002/pbc.20774

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Treating low-risk febrile neutropenia: Jenny's story.

Authors:  R Phillips; R Skinner; J C Chisholm
Journal:  Arch Dis Child       Date:  2007-01       Impact factor: 3.791

2.  Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.

Authors:  Rodolfo Rivas-Ruiz; Miguel Villasis-Keever; Guadalupe Miranda-Novales; Osvaldo D Castelán-Martínez; Silvia Rivas-Contreras
Journal:  Cochrane Database Syst Rev       Date:  2019-03-19

3.  Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.

Authors:  Kenneth V I Rolston; Susan E Frisbee-Hume; Shreyaskumar Patel; Ellen F Manzullo; Robert S Benjamin
Journal:  Support Care Cancer       Date:  2009-04-22       Impact factor: 3.603

Review 4.  Systematic review of reduced therapy regimens for children with low risk febrile neutropenia.

Authors:  Jessica E Morgan; Jemma Cleminson; Karl Atkin; Lesley A Stewart; Robert S Phillips
Journal:  Support Care Cancer       Date:  2016-01-13       Impact factor: 3.603

5.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Ottavio Ziino; Fabio Tucci; Mario Renato Rossi
Journal:  Pediatr Rep       Date:  2011-02-24

6.  Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia.

Authors:  S Cheng; O Teuffel; M C Ethier; C Diorio; J Martino; C Mayo; D Regier; R Wing; S M H Alibhai; L Sung
Journal:  Br J Cancer       Date:  2011-06-21       Impact factor: 7.640

Review 7.  Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.

Authors:  Liat Vidal; Itsik Ben Dor; Mical Paul; Noa Eliakim-Raz; Ellisheva Pokroy; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-09

8.  Beta-herpesviruses in febrile children with cancer.

Authors:  Stephanie Yee-Guardino; Kate Gowans; Belinda Yen-Lieberman; Pamela Berk; Debra Kohn; Fu-Zhang Wang; Lara Danziger-Isakov; Camille Sabella; Sarah Worley; Philip E Pellett; Johanna Goldfarb
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.